Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
The biotech delivered excellent news from the laboratory.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
What's breaking now, across thousands of outlets.
The biotech delivered excellent news from the laboratory.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
One turnaround story shows recovery despite revenue headwinds; the other leans on government contracts and strong cash flow. Their valuations tell very different stories.